Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
The LAMEA COPD & Asthma Device Market is expected to reach $ 6,951.1 Million by 2022 growing at a CAGR of 6.1% CAGR during 2016 - 2022. Increasing disposable income levels in emerging economies as well as developing countries has led to the increased usage of asthma pumps and sprays in these regions. However, the unknown etiology of asthma and COPD in medical industry may hamper the market growth in the next six years. Upcoming treatment methodologies such as once-a-day combination products and monoclonal antibodies have created new opportunities for the market growth. Additionally, pharmaceutical companies have been developing new bio-based medications in combination with bio-technology which promises immense growth opportunities along with sustainable development for asthma & COPD market over the next decade.
The report highlights the adoption of COPD & Asthma Devices in LAMEA (Latin America, Middle East and Africa). Based on the product type; the market is segmented into Inhalers and Nebulizers market. Further the Inhaler segment is sub segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers Market.
The countries included in the report are Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria and Rest of LAMEA. Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.
Global COPD and Asthma Devices Market